Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$18.73
▼ $0.22 (-1.2%)
Market data updated: 09/20 10:08 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/20/2026
Market Cap
$5.35B
Day Range
$18.66 - $19.01
52-Week Range
$13.09 - $19.85
Beta
—
Next Earnings
02.11.2026
Support
$16.83
Resistance
$19.79
SHC is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+17.3% (1Y)
Strengths: 13/30 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 68.8%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $2.43 vs. price $18.73 (-87.0%)
Fair Value
Signal tension
Growth scores strong (76/100), but fair-value analysis scores this stock as relatively expensive (33/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
62
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
76
Quality
58
Value
33
Momentum
62
Risk
42
Sentiment
100
Fundamental
63
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Sotera Health Company (SHC) has centered on its **Q2 2026 earnings performance**, highlighting broad-based growth across its core segments—particularly **Sterigenics (sterilization services)**, **Nordion (isotope supply)**, and **Nelson Labs (customer engagement improvements)**—which drove positive market reactions. Analysts noted strong revenue growth in Sterigenics (7% constant-currency increase) and Nordion’s demand for Cobalt-60. Additionally, there was brief mention of **insider selling** by Executive Chairman Michael Petras Jr. and general market comparisons, though no major financial or operational controversies were reported.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Sotera Health Company. News trend score: 100. Reason: 11 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
34
🎯 Conviction (vs. Emotion)
40
Psychology
51
Fundamentals
63
Technical
62
Valuation
33
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+18%
Market Narrative
77
Fundamental Reality
40
Narrative Gap
+37
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s extreme valuation (+664% above DCF) paired with weak momentum suggests traders may be overconfident in fundamentals despite recent price weakness. Herding behavior is present but muted, as the stock underperformed peers without extreme volume or sentiment. The narrative-reality gap (33) implies traders are prioritizing optimism over price action. The key question: *Will traders justify overvaluation with future growth, or will price correct?*
Updated: 09/09/2026, 07:30 AM
What could change this?
👥 What the crowd believes
"Michael Petras Jr, Executive Chairman, sold $21.17M of Sotera Health stock (article 3)"
"Revenue hit $321M with adjusted EPS up 30% year-over-year (article 11)"
"Sterigenics delivered 7% constant currency revenue growth (article 8)"
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Thorstein Veblen — 64/100
🔴 Weakest match
Benjamin Graham — 15/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among historical methodologies, with Samuel Armstrong Nelson standing out as the sole bullish voice, scoring an 85 and flagging a favorable cycle position. His technical-leaning approach contrasts sharply with the majority, including Graham (15) and Marks (24), who dismiss it outright for lacking defensive value or being late-cycle. Meanwhile, Lynch (63) and Veblen (64) see mixed potential—growth exists but is already priced in—while Fisher (56) and Bagehot (59) acknowledge solid fundamentals without calling it exceptional. The divide between cyclical optimists like Nelson and value purists like Graham highlights whether this stock’s momentum or structural weaknesses dominate, with even moderate-risk investors like Loeb (46) and Housel (50) treating it as a cautious hold rather than a high-conviction pick.
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 64
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 63
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 63
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 59
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 56
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 52
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 51
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 50
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 46
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 46
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 45
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 33
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 30
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 24
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 15
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (5 bullish · 3 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
55.5%
Operating Margin
25.4%
Net Margin
6.7%
EBITDA Margin
—
ROE
12.9%
ROA
2.4%
ROIC
—
EPS
$0.27
Cash
$344.62M
Total Debt
$2.14B
Current Ratio
2.46
Debt/Equity
3.69
How is Fair Value calculated? →
Current Price
$18.73
Estimated Fair Value (DCF)
$2.43
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-87.0%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
5.1%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 5.1% | $156.72M | $143.78M |
| 2 | 4.4% | $163.63M | $137.73M |
| 3 | 3.8% | $169.81M | $131.13M |
| 4 | 3.1% | $175.14M | $124.08M |
| 5 | 2.5% | $179.52M | $116.68M |
Base FCF (last actual year)
$149.18M
Terminal Value
$2.83B
Present Value of Terminal Value
$1.84B
Enterprise Value
$2.49B
Net Debt
$1.80B
Equity Value
$697.21M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$2.13
Tangible Book Value per Share (Tangible NAV)
$1.14
Sentiment based on basic keywords (not AI) — 11 positive, 7 neutral, 2 negative out of the last 20 articles.
SeekingAlpha · 18.9.2026
Insider Monkey · 15.9.2026
Yahoo · 15.9.2026
StockStory · 14.9.2026
Yahoo · 14.9.2026
SeekingAlpha · 9.9.2026
Yahoo · 24.8.2026
StockStory · 24.8.2026
Benzinga · 20.8.2026
Yahoo · 19.8.2026
StockStory · 19.8.2026
Yahoo · 16.8.2026
StockStory · 16.8.2026
Yahoo · 15.8.2026
StockStory · 15.8.2026
Motley Fool · 13.8.2026
Yahoo · 13.8.2026
Benzinga · 12.8.2026
StockStory · 12.8.2026
Yahoo · 12.8.2026
Sotera Health Company (SHC) currently has a StockIQ AI score of 62/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
SHC currently scores 62/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, SHC's estimated fair value is $2.43, which is 87.0% below the current price of $18.73. This is one valuation model among several signals in the fair-value category, not a price target.
SHC's technical score is 62/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 68.8%; Free cash flow growth: 230.8%; Net income growth: 75.6%.
Based on the real signals StockIQ computed: Estimated fair value: $2.43 vs. price $18.73 (-87.0%); Calmar: 0.16 (3y annualized return 7.0% / max drawdown 43.5%); Debt/equity: 3.69.
StockIQ has no recorded dividend payment history for SHC.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 4 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Petras Michael B. Jr. | Open Market Sale | 17.8.2026 | 850,000 | -850,000 | $18.50 |
| Petras Michael B. Jr. | Open Market Sale | 17.8.2026 | 294,515 | -294,515 | $18.50 |
| Rutz Michael P | Open Market Sale | 7.8.2026 | 150,000 | -150,000 | $18.84 |
| Rutz Michael P | Open Market Sale | 7.8.2026 | 334,279 | -150,000 | $18.84 |
| Lyons Jonathan M. | Tax Withholding in Shares | 5.8.2026 | 11,316 | -11,316 | $17.98 |
| Lyons Jonathan M. | Tax Withholding in Shares | 5.8.2026 | 217,304 | -11,316 | $17.98 |
| SHADER ALTON | Grant/Award from Employer | 26.5.2026 | 203,634 | +203,634 | — |
| SHADER ALTON | Grant/Award from Employer | 26.5.2026 | 101,817 | +101,817 | — |
| SHADER ALTON | Grant/Award from Employer | 26.5.2026 | 375,939 | +375,939 | — |
| SHADER ALTON | Grant/Award from Employer | 26.5.2026 | 375,939 | +375,939 | — |
| SHADER ALTON | Grant/Award from Employer | 26.5.2026 | 579,573 | +203,634 | — |
| SHADER ALTON | Grant/Award from Employer | 26.5.2026 | 101,817 | +101,817 | — |
| Chen Ruoxi | Grant/Award from Employer | 22.5.2026 | 14,970 | +14,970 | — |
| Klee Ann R. | Grant/Award from Employer | 22.5.2026 | 14,970 | +14,970 | — |
| Simon, Christopher | Grant/Award from Employer | 22.5.2026 | 14,970 | +14,970 | — |
| Krause Kenneth D. | Grant/Award from Employer | 22.5.2026 | 14,970 | +14,970 | — |
| Wheadon David E. | Grant/Award from Employer | 22.5.2026 | 14,970 | +14,970 | — |
| PETRELLA VINCENT K | Grant/Award from Employer | 22.5.2026 | 14,970 | +14,970 | — |
| Neary James | Grant/Award from Employer | 22.5.2026 | 14,970 | +14,970 | — |
| Flynn Karen | Grant/Award from Employer | 22.5.2026 | 14,970 | +14,970 | — |
| CUNNINGHAM SEAN LAURENCE | Grant/Award from Employer | 22.5.2026 | 14,970 | +14,970 | — |
| Kyle Richard G | Grant/Award from Employer | 22.5.2026 | 14,970 | +14,970 | — |
| PETRELLA VINCENT K | Grant/Award from Employer | 22.5.2026 | 95,751 | +14,970 | — |
| Neary James | Grant/Award from Employer | 22.5.2026 | 95,751 | +14,970 | — |
| Kyle Richard G | Grant/Award from Employer | 22.5.2026 | 14,970 | +14,970 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
11,959,887 shares short as of 2026-08-31 · vs. 14,381,320 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
71.1% of trading volume this week was short selling, vs. 67.1% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology